Chief investigatorRury Holman
Sponsor:University of Oxford
Funder:British Heart Foundation
Aspirin, a medicine that reduces platelet activity, is recommended for people with diabetes who already have heart disease in order to reduce their likelihood of having a further heart attack or stroke. Whether aspirin reduces the risk of a first heart attack or a first stroke in people with diabetes is unclear.
This study, conducted in people with diabetes who did not have heart disease, compared the ability of aspirin 100 mg once daily, aspirin 200 mg once daily or aspirin 100 mg twice daily to reduce platelet activity.
Double-blind, randomised, three-way cross-over, interventional clinical trial.
Aspirin 100mg twice-daily reduced platelet reactivity more effectively than 100mg once-daily, and numerically more than 200mg once-daily. Clinical outcome trials evaluating primary cardiovascular prevention with aspirin may need to consider using more frequent doses. The published results are available here.
A clinical trial run by DTU's Translational Research Group (TRG) has featured in the local media in the hope that it encourages people to take part.
Funded by the British Heart Foundation, the study aims to find out if changing the way we give aspirin to people with type 2 diabetes could help protect them from heart attacks and strokes....